James Malone, DO
Family Medicine · Bridgeport, WVNPI 1134225832
Payments from drug & device makers
Across 346 payments — averaging $15.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$918
- AbbVie$813
- Astellas Pharma US Inc$803
- Pfizer$439
- Exact Sciences$354
- Shield Therapeutics Inc$229
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,444100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 49 | $918 |
| AbbVie(2 entities) | 64 | $813 |
| Astellas Pharma US Inc | 57 | $803 |
| Pfizer | 25 | $439 |
| Exact Sciences | 25 | $354 |
| Shield Therapeutics Inc | 7 | $229 |
| Boehringer Ingelheim | 15 | $202 |
| Novartis | 14 | $194 |
| AstraZeneca | 11 | $194 |
| Amgen | 9 | $157 |
| GSK | 9 | $145 |
| Johnson & Johnson | 6 | $114 |
| Bayer | 7 | $110 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $95 |
| Esperion Therapeutics, Inc. | 5 | $94 |
| Lilly USA, LLC | 6 | $81 |
| Abbott | 4 | $75 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $56 |
| Phathom Pharmaceuticals, Inc. | 3 | $50 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Dexcom, Inc. | 3 | $40 |
| Amarin Pharma, Inc. | 2 | $37 |
| Ironwood Pharmaceuticals, Inc | 2 | $33 |
| Merck | 2 | $30 |
| Eisai Inc. | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Sanofi-aventis U.S. LLC | 2 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Verona Pharma, Inc. | 1 | $16 |
| Mylan Specialty L.p. | 1 | $14 |
| Dynavax Technologies Corporation | 1 | $11 |
How this compares
$5,444 in reported general payments places this provider in the 90th percentile of 843 family medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 548 | $280,263 |
| EliquisApixaban | 625 | $195,166 |
| OzempicSemaglutide | 139 | $137,734 |
| XareltoRivaroxaban | 310 | $104,135 |
| XifaxanRifaximin | 70 | $67,554 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $60,504 |
| Breo ElliptaFluticasone/Vilanterol | 86 | $48,440 |
| LinzessLinaclotide | 59 | $42,764 |
| JanuviaSitagliptin Phosphate | 54 | $42,535 |
| EntrestoSacubitril/Valsartan | 84 | $39,261 |
| TrulicityDulaglutide | 20 | $37,873 |
| MyrbetriqMirabegron | 85 | $36,686 |
| FarxigaDapagliflozin Propanediol | 51 | $33,015 |
| Repatha SureclickEvolocumab | 38 | $32,126 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 83 | $25,209 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $202 | $287,478562 claims |
| PfizerEliquis | $439 | $195,166625 claims |
| Novo NordiskOzempic, Rybelsus | $918 | $154,380154 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Incruse Ellipta | $145 | $142,657252 claims |
| Johnson & JohnsonXarelto | $114 | $104,135310 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $56 | $67,55470 claims |
| MerckJanuvia, Janumet | $30 | $55,93166 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $81 | $53,70832 claims |
| AstraZenecaFarxiga, Lokelma | $194 | $43,73070 claims |
| AbbVieLinzess | $813 | $42,76459 claims |
| NovartisEntresto | $194 | $39,26184 claims |
| Astellas Pharma US IncMyrbetriq | $803 | $36,68685 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 843 family medicine providers in West Virginia.
Other family medicine in Bridgeport
- David HessBridgeport$20K
- Frances MurrayBridgeport$10K
- Stephen FryerBridgeport$9K
- Brittanie WestBridgeport$8K
- Wilbur SineMorgantown$179K
- Dorian WilliamsMorgantown$169K
- Julie DetempleSouth Charleston$129K
- Clemente DiazRichwood$127K
- John CornellHuntington$94K
- Mark CucuzzellaHarpers Ferry$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.